AstraZeneca announced that the EC green-lighted the new formulation of the once-weekly type-2 diabetes injection, which will be marketed as Bydureon BCise (exenatide 2mg prolonged-release suspension).

A rigorous study that randomly assigned Parkinson’s patients to take exenatide, a relative of Ozempic, showed absolutely no benefit or slowing of the course of the degenerative disease after 96 ...

manage blood sugar levels in people with type 2 diabetes Yes* exenatide (Bydureon BCise) manage blood sugar levels in people with type 2 diabetes Yes* * Hair loss was not reported in the clinical ...

Objective–To investigate the effect of treatment with the glucagon-like peptide 1 receptor agonist exenatide on weight loss and metabolic parameters in obese nondiabetic women. Research Design ...

A phase 3 randomized controlled trial found no significant improvements with the GLP-1 exenatide in this population. Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by UCL researchers. The world's largest and longest ...